<DOC>
	<DOCNO>NCT02626026</DOCNO>
	<brief_summary>This study consist two part : Part A evaluate safety , tolerability , pharmacokinetics ( PK ) , pharmacodynamics ( PD ) GS-4059 healthy participant . Part B evaluate safety , tolerability , effect GS-4059 disease-specific clinical marker outcomes participant rheumatoid arthritis ( RA ) .</brief_summary>
	<brief_title>Safety Pharmacokinetics GS-4059 Healthy Volunteers Subjects With Rheumatoid Arthritis ( RA )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Inclusion Criteria Part A Be nonsmoker Have calculate body mass index ( BMI ) 19 30 kg/m^2 , inclusive , screen Have creatinine clearance ( CrCl ) ≥ 90 mL/min ( use CockcroftGault method base serum creatinine actual body weight measure screen Females childbearing potential must negative serum pregnancy test screen clinic admission . Male female individual childbearing potential engage heterosexual intercourse must agree use protocol specify method ( ) contraception Must , opinion investigator , good health base upon medical history physical examination , include vital sign Screening laboratory evaluation ( hematology include reticulocyte , fast lipid , chemistry , urinalysis ) must fall within normal range local laboratory 's reference range unless result determine investigator clinical significance Have either normal 12lead ECG one abnormality consider clinically insignificant investigator consultation Sponsor Part B Diagnosis RA ( accord 1987 ACR classification criterion OR score ≥ 6 defined ACR/European League Against Rheumatism Classification Diagnostic Criteria RA ) Individuals must take methotrexate ( MTX ) 7.5 25 mg/week continuously least 12 week , least 6 week stable dose prior first study drug dose throughout study duration . Individuals must receive folic folinic acid supplementation stable dose least 6 week prior Day 1 dose throughout study duration Individuals allow remain antimalarial therapy , least 8 week stable dose prior first study drug dose Use oral corticosteroid 10 mg prednisone equivalent per day allow dose stable least 28 day prior first study drug dose Nonsteroidal antiinflammatory drug ( NSAIDs ) analgesic ( include aspirin ≤ 100 mg daily ) allow dos stable least 14 day prior first dose study drug Estimated creatinine clearance ( CLCr ) ≥ 60 mL/min ( use CockcroftGault method ) base serum creatinine actual body weight measure screen evaluation White blood cell ( WBC ) , neutrophil count , lymphocyte count , platelet count ≥ 0.75 x low limit normal ( LLN ) A negative serum pregnancy test screen negative pregnancy test Day 1 visit prior first dose study drug female individual child bear potential . Male female individual childbearing potential engage heterosexual intercourse must agree use protocol specify method ( ) contraception Exclusion Criteria Part A Pregnant lactating individual Have serious active medical psychiatric illness ( include depression ) , opinion Investigator , would interfere individual 's treatment , assessment , compliance protocol . This would include renal , cardiac , hematological , hepatic , pulmonary ( include chronic asthma ) , endocrine ( include diabetes ) , central nervous , gastrointestinal ( include ulcer ) , vascular , metabolic ( thyroid disorder , adrenal disease ) , immunodeficiency disorder , active infection , malignancy clinically significant require treatment Positive test drug abuse , include alcohol screen Day 1/checkin A positive test result human immunodeficiency virus ( HIV1 ) antibody , hepatitis B ( HBV ) surface antigen hepatitis C ( HCV ) antibody Have poor venous access limit phlebotomy Have take prescription medication overthecounter medication , include herbal product , within 28 day prior start study drug dosing , exception vitamin and/or acetaminophen and/or hormonal contraceptive medication Have treat systemic steroid , immunosuppressant therapy , chemotherapeutic agent within 3 month prior Screening expect receive agent study ( eg , corticosteroid , immunoglobulin , immune cytokinebased therapy ) Significant drug sensitivity drug allergy ( anaphylaxis hepatoxicity ) Medical surgical treatment permanently alter gastric absorption ( eg , gastric intestinal surgery ) ; history cholecystectomy exclusionary Part B Known hypersensitivity formulation excipient . Pregnant lactating female Previous treatment Bcell deplete agent ( eg , rituximab ) within 12 month treatment Prior treatment commercially available investigational Bruton 's tyrosine kinase ( BTK ) inhibitor Diagnosis diabetes , history impair glucose tolerance test , history abnormal HgA1c , history impair fast glucose Current treatment disease modify antirheumatic drug ( DMARD ) MTX hydroxychloroquine , unless appropriate wash Current treatment biologic agent , unless appropriate wash Any laboratory abnormality condition , investigator 's opinion , could adversely affect safety individual impair assessment study result History current inflammatory joint disease , RA Active significant systemic involvement secondary RA vasculitis , pulmonary fibrosis Felty 's syndrome History current autoimmune rheumatic disorder , RA RA functional class 4 uncontrolled medical condition History ongoing , chronic recurrent infection recent serious lifethreatening infection Presence condition could , opinion investigator , compromise individual 's ability participate study , history substance abuse , alcoholism , psychiatric condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>